---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-023991"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T07:05:09.625889+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TriSalus appoints Dr. Richard Marshall as CMO, effective June 29, 2026

## Summary
- Annual base salary of $525,000; sign-on bonus of $250,000.
- Eligible for annual bonus up to 50% of base salary based on board-determined goals.
- Board will recommend granting 120,000 stock options and 60,000 restricted stock units.
- Marshall, previously Medical Director since Jan 2025, will lead medical strategy and clinical development.
- Appointment strengthens leadership as TriSalus advances its PEDD platform for solid tumors.

## SEC filing metadata
- accession: 0001628280-26-023991
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000162828026023991/0001628280-26-023991-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000162828026023991/tlsi-20260401.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-023991
- JSON: https://secwatch.observer/filing/0001628280-26-023991.json
- Plain text: https://secwatch.observer/filing/0001628280-26-023991.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.